Sonidegib in Locally Advanced Basal Cell Carcinoma: A Monocentric Retrospective Experience and a Review of Published Real-Life Data

Basal cell carcinoma (BCC) represents the most common skin cancer and locally advanced BCC (laBCC) refers to an aggressive, large, infiltrative that cannot be treated by surgery or radiotherapy. Sonidegib is a Hedghehog inhibitor (HHi) indicated for laBCC. This monocentric retrospective real-life study of laBCCs receiving treatment. Although widely used, since its approval Food Drug Administration in 2015, only limited number experiences have been reported. Eleven patients, including four patients diagnosed with Cell Naevus syndrome, received treatment laBCCs. Seven (63.6%) experienced adverse events (AEs) but three had discontinue were therefore excluded from following results. Four (50%) achieved complete clinical remission (CR); all cases was confirmed biopsy. Partial response (PR) found out eight (37.5%). One patient (12.5%) showed steady disease (SD). None signs progression during HHi. same efficacy treating as already seen trials. All suffering syndrome control being Sonidegib. Consequently, we strongly advise joint management through multidisciplinary team whenever feasible.